A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus

Clinical trial NCT06097299 · COMPLETED

Trial details

NCT number: NCT06097299
Sponsor: ModernaTX, Inc.
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Respiratory Syncytial Virus

Start date: 2023-10-24
Primary completion: 2025-06-27
Enrollment: 349

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.